Arcturus Therapeutics Holdings Inc. (ARCT)
| Market Cap | 250.69M |
| Revenue (ttm) | 82.03M |
| Net Income (ttm) | -65.78M |
| Shares Out | 28.42M |
| EPS (ttm) | -2.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 269,829 |
| Open | 8.30 |
| Previous Close | 8.30 |
| Day's Range | 8.28 - 8.88 |
| 52-Week Range | 5.85 - 24.17 |
| Beta | 2.44 |
| Analysts | Buy |
| Price Target | 24.11 (+173.36%) |
| Earnings Date | May 7, 2026 |
About ARCT
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In additi... [Read more]
Financial Performance
In 2025, ARCT's revenue was $82.03 million, a decrease of -46.14% compared to the previous year's $152.31 million. Losses were -$65.78 million, -18.73% less than in 2024.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for ARCT stock is "Buy." The 12-month stock price target is $24.11, which is an increase of 173.36% from the latest price.
News
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of live...
Arcturus Therapeutics Holdings Transcript: The 38th Annual Roth Conference
The company is refocusing on rare diseases with its mRNA platform, advancing ARCT-810 for OTC deficiency and ARCT-032 for cystic fibrosis. Regulatory clarity for pediatric trials is expected in Q2 2024, and the cash runway extends into Q2 2028, with additional funding likely needed for late-stage trials.
Arcturus Therapeutics Holdings Transcript: Leerink Global Healthcare Conference 2026
Recent progress includes well-tolerated phase II CF dosing, early efficacy signals, and a 12-week study with expanded endpoints and sites. The OTC program is prioritizing pediatric development, pending FDA guidance. KOSTAIVE vaccine approvals continue, with financial runway into Q2 2028, excluding arbitration outcomes.
Arcturus Therapeutics to Attend Upcoming Investor Conference
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of live...
Arcturus Therapeutics Holdings Earnings Call Transcript: Q4 2025
ARCT-032 and ARCT-810 mRNA programs advanced, with a 12-week CF phase II study set for 2026 and regulatory clarity for OTC deficiency expected. Revenue and expenses declined year-over-year, cash runway extended to Q2 2028, and KOSTAIVE COVID-19 vaccine approved in the UK.
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of live...
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the developm...
Arcturus Therapeutics Holdings Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Advanced mRNA therapeutics for rare diseases are progressing, with a pivotal phase IIb CF trial starting soon and regulatory clarity for the OTC deficiency program expected in the first half of the year. Strong financials support a focused, lean operation.
Arcturus Therapeutics Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company is advancing innovative mRNA therapies for cystic fibrosis and OTC deficiency, with strong interim clinical data and regulatory milestones targeted for 2026. Financial stability supports key studies and ongoing platform innovation.
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the developm...
Arcturus Therapeutics Holdings Earnings Call Transcript: Q3 2025
Q3 revenue and expenses declined year-over-year, with a net loss of $13.5M. ARCT-032 and ARCT-810 programs advanced, while Kostaive's US launch faces regulatory delays. Cash runway extends into 2028, supporting global trial expansion.
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the developm...
Arcturus Therapeutics to Attend Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the developm...
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the developm...
Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stock was trading lower on Wednesday after the company shared interim results from its ongoing Phase 2 trial of ARCT-032, an investigational inhaled m...
Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results
Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) tumbled by more than 56% on Wednesday after the company reported interim results from its Phase 2 study of ARCT-032, an inhaled mRNA therap...
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the developm...
Arcturus Therapeutics Holdings Earnings Call Transcript: Q2 2025
Advanced CF and OTC programs with positive interim data and regulatory progress; revenue and expenses declined year-over-year, extending cash runway into 2028. Key vaccine programs and leadership changes support a strong outlook.
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the developm...
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the developm...
Arcturus Therapeutics Holdings Transcript: Status Update
ARCT-810 demonstrated significant reductions in glutamine and increases in ureagenesis, indicating improved urea cycle function and metabolic control in OTC deficiency. The therapy was well tolerated, with robust biomarker data supporting its potential as a transformative treatment.
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the developm...
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Arcturus--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development o...
Arcturus Therapeutics Holdings Earnings Call Transcript: Q1 2025
Prioritized CF and OTC programs, reduced costs, and extended cash runway to Q1 2028. Q1 2025 revenue declined year-over-year as KOSTAIVE transitioned to commercialization, with EU approval triggering a milestone payment. Interim data for key programs expected mid-2025.
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the developm...